Fragmentomics by Liqomics
Exciting News: Fragmentomics by Liqomics We are thrilled to announce that our project, Fragmentomics by LIQOMICS, has been...
LIQOMICS The future of minimal residual disease in cancer.
At LIQOMICS we strive to improve cancer treatment. Requiring only a blood sample, we use circulating tumor DNA (ctDNA) to understand the genetics of individual cancer, detect minimal residual disease (MRD), and monitor treatment with razor-sharp sensitivity.
About
Cutting-edge liquid biopsy technology for genotyping and disease monitoring
LIQOMICS is an academic spin-off company from Cologne, Germany. We aspire to bring our cutting-edge liquid biopsy technology for genotyping and disease monitoring to patients worldwide.
Meet LIQOMICS at Top Global Conferences in 2025!
Let’s arrange a meeting at one of the following events:
- May 7–9 | Liquid Biopsy from Discovery to Clinical Residual Cancer, Nice, France
- May 30–June 3 | ASCO2025 Annual Meeting, Chicago, IL & online
- June 12–15 | 30th EHA Congress, Milan, Italy
- June 17–21 | 18th International Conference on Malignant Lymphoma, Lugano, Switzerland
- October 17–21 | ESMO Congress 2025, Berlin, Germany
- December 6–9 | 67th ASH Annual Meeting and Exposition, Orlando, Florida
Schedule a meeting with us today and discover how LIQOMICS can support your R&D goals!
LIQOMICS is an academic spin-off company from Cologne, Germany. We aspire to bring our cutting-edge liquid biopsy technology for genotyping and disease monitoring to patients worldwide.
Highly sensitive minimal residual disease (MRD) detection
The Liqomics MRD test is a crucial tool for the early detection of low level MRD in cancer patients. With our proprietary workflow and bioinformatics we detect cancer with higher sensitivity than others. This can enable an earlier intervention in case of a relapse and hence an improved disease outcome for the patients.
Some key statistics of our assay
Sensitivity for Genotyping (SNPs / InDels) > 93%
Specificity for Genotyping (SNPs / InDels) > 99.999%
Sensitivity for MRD detection at MRD level > 10-5 > 88%
Specificity for MRD detection at MRD level > 10-5 > 99%
Limit of Detection for MRD ~ 5 x 10-6
What makes us different
Our proprietary technology allows us to be more sensitive and specific when it comes to genotyping and minimal residual disease (MRD) detection across cancers. This is crucial in situations of low disease burden.
LIQOMICS
COMPETITORS
Input Material
Only blood needed
Often tumor tissue needed
Detection Threshhold
Few DNA molecules per million (10-6)
Mostly higher (10-3-10-5)
Applicability
All cancers
Often only specific cancers
Design Principle
Universal assay for all patients with a type of cancer
Often patient-individual assay with high assay costs
Features
MRD, Genotying and additional bespoke features easily possible
often only one feature
LIQOMICS
COMPETITORS
Applicability
Platform applicable to all cancers
Often only applicable to specific cancers
Features
MRD, Genotyping, additional features possible
Often only MRD or Genotyping
Design principle
Universal assay for all patients with a particular cancer or group of cancers making assay cheaper
Often individual assay for patients needed with high assay costs
Detection threshold for MRD
Few cancer DNA molecules per million (10-6)
Mostly higher (10-3-10-5)
Input material
Only blood needed
Often tumor-informed approach, tumor tissue needed
Learn more about our assay
Our assay uses tumor mutations that we identify and track in blood to inform on the genetic drivers of a tumor and to quantify minimal residual disease (MRD)
Publications
Here are some publications from our early development showing applications in Hodgkin Lymphoma and CNS Lymphoma.
Testimonials
What Clients Say About Us
Vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint eiusmod tempor incididunt ut labore et dolore magna aliqua
Vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint eiusmod tempor incididunt ut labore et dolore magna aliqua
Vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint eiusmod tempor incididunt ut labore et dolore magna aliqua
Our Blog
Lates News & Articles
Zirkulierende Tumor-DNA (ctDNA)
Die Zukunft der Krebsdiagnostik: Zirkulierende Tumor-DNA (ctDNA) (Teil II) In unserem letzten Artikel haben wir die Grundlagen der...
LymphoVista HL assay at the ASH 2024, MRD in Hodgkin Lymphoma
LymphoVista HL Assay results presented at ASH 2024 Annual Meeting Liqomics, a leading innovator in cancer diagnostics, is...